Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4017 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Nuvo completes Pennsaid safety data analysis

The phase III trial, named Study 112E, was a long-term multi-center, single-arm safety study of Pennsaid applied by patients with symptoms of osteoarthritis (OA) of the knee. In

Anadys reports encouraging hepatitis trial results

Results of the clinical trial, which investigated the safety, tolerability and anti-viral activity of ANA380, an oral prodrug of ANA317 (LB80317), in patients with lamivudine-resistant hepatitis B virus

ConjuChem up on positive diabetes data

Preliminary data from the phase I/II single escalating dose clinical study demonstrated an excellent tolerability profile and positive efficacy on glucose reduction supporting once-a-week dosing. Furthermore, the longer

Point presents promising talabostat data

Talabostat inhibits dipeptidyl peptidases (DPPs), which are enzymes that regulate biological processes, including tumor growth and immune responses. As a stromal targeted agent, talabostat inhibits fibroblast activation protein

Court rules against Lilly in Emisphere suit

The court re-affirmed its January 2006 ruling, stating that the patent related to the use of Emisphere's proprietary technology with GLP molecules belonged to Emisphere under the terms

CardioVascular Bio begins back pain studies

Chronic back pain, estimated to affect 26 million Americans, has recently been linked to blockage of blood vessels supplying the lower back, leading to a condition referred to